Stay on top of updates and innovations in the oncology landscape and how it impacts your decisions
How is the market changing and what do developers need to do?
DRG’s AML expert Dr. Jorrit Schafer talks to Dr. Andrew Merron about:
– The most transformational AML therapies recently approved
– Where the AML competitive landscape is heading
– Key takeaways for biopharma developers